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RESEARCH
Performance of prediction models for nephropathy in people 
with type 2 diabetes: systematic review and external validation 
study
Roderick C Slieker,1,2 Amber A W A van der Heijden,3 Moneeza K Siddiqui,4  
Marlous Langendoen-Gort,3 Giel Nijpels,3 Ron Herings,1,5 Talitha L Feenstra,6,7  
Karel G M Moons,8,9 Samira Bell,4 Petra J Elders,3 Leen M ’t Hart,1,2,10 Joline W J Beulens1,8
ABSTRACT
OBJECTIVES
To identify and assess the quality and accuracy of 
prognostic models for nephropathy and to validate 
these models in external cohorts of people with type 
2 diabetes.
DESIGN




Studies describing the development of a model to 
predict the risk of nephropathy, applicable to people 
with type 2 diabetes.
METHODS
Screening, data extraction, and risk of bias 
assessment were done in duplicate. Eligible models 
were externally validated in the Hoorn Diabetes 
Care System (DCS) cohort (n=11 450) for the same 
outcomes for which they were developed. Risks of 
nephropathy were calculated and compared with 
observed risk over 2, 5, and 10 years of follow-up. 
Model performance was assessed based on intercept 
adjusted calibration and discrimination (Harrell’s C 
statistic).
RESULTS
41 studies included in the systematic review 
reported 64 models, 46 of which were developed 
in a population with diabetes and 18 in the general 
population including diabetes as a predictor. The 
predicted outcomes included albuminuria, diabetic 
kidney disease, chronic kidney disease (general 
population), and end stage renal disease. The 
reported apparent discrimination of the 46 models 
varied considerably across the different predicted 
outcomes, from 0.60 (95% confidence interval 
0.56 to 0.64) to 0.99 (not available) for the models 
developed in a diabetes population and from 0.59 
(not available) to 0.96 (0.95 to 0.97) for the models 
developed in the general population. Calibration 
was reported in 31 of the 41 studies, and the 
models were generally well calibrated. 21 of the 64 
retrieved models were externally validated in the 
Hoorn DCS cohort for predicting risk of albuminuria, 
diabetic kidney disease, and chronic kidney disease, 
with considerable variation in performance across 
prediction horizons and models. For all three 
outcomes, however, at least two models had C 
statistics >0.8, indicating excellent discrimination. In 
a secondary external validation in GoDARTS (Genetics 
of Diabetes Audit and Research in Tayside Scotland), 
models developed for diabetic kidney disease 
outperformed those for chronic kidney disease. 
Models were generally well calibrated across all three 
prediction horizons.
CONCLUSIONS
This study identified multiple prediction models to 
predict albuminuria, diabetic kidney disease, chronic 
kidney disease, and end stage renal disease. In the 
external validation, discrimination and calibration 
for albuminuria, diabetic kidney disease, and chronic 
kidney disease varied considerably across prediction 
horizons and models. For each outcome, however, 
specific models showed good discrimination and 
calibration across the three prediction horizons, 
with clinically accessible predictors, making them 




People with type 2 diabetes are at high risk of 
microvascular and macrovascular complications.1  2 
About 25-35% of people with type 2 diabetes develop 
nephropathy,3-5 one of the leading causes of end stage 
renal disease, which is associated with a low quality 
of life and high mortality.6-9 As renal histological 
changes might already be advanced by the time 
a decline in renal function is detected,10-12 early 
identification of those at risk is essential to initiate 
targeted preventive treatment. Moreover, interventions 
are more effective at earlier than more advanced stages 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
People with type 2 diabetes are at increased risk of nephropathy
Many studies developed prediction models to identify those at high risk of 
nephropathy in people with type 2 diabetes or with diabetes as a predictor in the 
model
These models can be used in clinical practice provided that they are also 
accurate in external target populations
WHAT THIS STUDY ADDS
This study identified many studies that developed prognostic models to predict 
nephropathy in people with type 2 diabetes or with diabetes as a risk factor with 
variable performance across time horizons and models
Several models showed good performance in people with type 2 diabetes across 
various prediction horizons for different nephropathy outcomes,
Models, however, performed best at the two year horizon and for diabetic kidney 
disease as outcome
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of nephropathy.7 13 Decisions for interventions can 
be achieved by regularly estimating an individual’s 
risk of nephropathy based on validated prediction 
models. These prediction models should preferably be 
based on routine clinical markers and not expensive 
biomarkers, given that routine and low cost markers 
will be easier to implement into clinical practice.
Preventive treatment includes intensified glycaemic 
control, nephroprotective glucose lowering drugs 
such as glucagon-like peptide 1 receptor antagonists 
and sodium-glucose cotransporter 2 inhibitors, 
blood pressure control, and inhibition of the renin-
angiotensin system.14-17 Moreover, treatment with 
glucose lowering drugs such as sodium-glucose 
cotransporter 2 inhibitors has been suggested to 
prevent the progression of renal disease.18 Treatment 
of end stage renal disease comprises renal replacement 
therapy with dialysis and transplantation.7 19 The 
efficacy of renal replacement therapy, however, has 
been shown to be worse in people with diabetes.4
Prediction models for nephropathy allow the 
accurate estimation of nephropathy risk in people with 
type 2 diabetes. To ensure reliability though, developed 
prediction models need to be externally validated 
in their targeted populations, and ideally compared 
head to head on their predictive performance.20 21 
Only when proven valid in external validation, can 
prediction models be considered relevant to clinical 
practice to improve decision making and improve the 
cost effectiveness of care. Several prediction models for 
renal impairment and nephropathy in people with type 
2 diabetes or applicable to this population have been 
developed.
Known risk factors for diabetic nephropathy 
include urinary albumin excretion, glucose levels, 
blood pressure, dyslipidaemia, obesity, smoking, 
duration of diabetes, age, sex, and retinopathy.22 More 
recently, identified risk factors include oxidative stress, 
inflammation, genetic background, ethnicity, and 
glomerular hyperfiltration.22
Several systematic reviews on prognostic models 
for nephropathy have been performed,23-25 although 
several years ago23 25 26 or focusing only on the 
general population.24 Also, although some external 
validation of the models has been done, it was 
either limited to the general population24 26 27 or 
only included a small number of (other) models as 
part of a model development paper.28 Given that 
people with type 2 diabetes have an increased risk of 
developing nephropathy, it is important to assess the 
performance of prognostic models in a head-to-head 
comparison in a large scale population of those with 
type 2 diabetes. We therefore systematically reviewed 
existing prediction models for nephropathy applicable 
to people with type 2 diabetes. The retrieved models 
were appraised on quality and subsequently validated 
and compared head to head in the Hoorn DCS cohort, 
a prospective cohort of more than 14 000 people 
from the Hoorn region in the Netherlands.29 Finally, 
we validated the top performing models in GoDARTS 
(Genetics of Diabetes Audit and Research in Tayside 
Scotland), a secondary prospective cohort from 
Scotland.30
Methods
We carried out a systematic review and external 
validation study. This systematic review was performed 
according to guidance of the Cochrane Prognosis 
Methods Group (methods.cochrane.org/prognosis) 
and reported to the criteria of the preferred reporting 
items for systematic reviews and meta-analyses 
statement and a measurement tool to assess systematic 
reviews guidelines.31-33 The external validation study 
was reported in line with the transparent reporting 
of a multivariable prediction model for individual 
prognosis or diagnosis guideline (supplementary 
tables S1 and S2).34 35
Search strategy
We systematically searched PubMed and Embase from 
inception until 16 June 2020 to identify prediction 
models for the risk of developing nephropathy 
applicable to people with type 2 diabetes. This 
systematic literature search was based on a predefined 
search string that was specifically developed for both 
databases (supplementary table S3). Online software, 
covidence (Melbourne, Australia), was used to perform 
a systematic review of identified development studies.
Study selection
Four researchers (MLG, AAvdH, RCS, and JWJB) 
independently reviewed in duplicate the title, abstract, 
and full text article of retrieved studies. Disagreements 
between two reviewers were resolved by consensus 
with a third reviewer. A study was included when 
the prediction model was developed in a population 
in which the majority of people had a diagnosis of 
type 2 diabetes, or in the general population, and 
included diabetes as a predictor; the risk of developing 
nephropathy could be calculated from the reported 
prediction model or rule; nephropathy was the 
outcome of the model; and follow-up was longer than 
one year. We also included studies for which the type 
of diabetes was not specified but was probably type 
2 diabetes based on the population age. Excluded 
studies were those performed in populations restricted 
to other forms of diabetes. A study was also excluded 
when it was conducted in animals, it was not written in 
English or Dutch, the prediction model was developed 
in a population with other physical severe conditions 
or in a postsurgical population, a new predictor 
was added to an original model, or the model only 
consisted of one predictor. In addition, reference lists 
of all screened full text articles and relevant systematic 
reviews were assessed for additional eligible studies. 
Any study type other than cross sectional (ie, without 
patient follow-up) was included—namely, randomised 
trials, cohort studies, and registry based studies.
Data extraction
Data from the included studies were systematically 
extracted according to the criteria of the checklist for 
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critical appraisal and data extraction for systematic 
reviews of prediction modelling studies checklist.36 
This checklist includes specifics about the research 
design, study population, outcome of the model, 
predictors, sample size, missing values, model 
development, performance of the model, model 
validation, results, and interpretation of the model. 
MLG, JWJB, and AAvdH extracted data on all these 
domains in duplicate from the included studies.
Quality assessment
Risk of bias and concern for applicability was assessed 
with the prediction model risk of bias assessment 
tool, which was specifically developed to assess 
diagnostic and prognostic prediction models.37 38 
This tool consists of 20 items and includes specifics 
about the research design, study population, outcome 
of the model, predictors, handling of the data, and 
performance measures. MLG, AAvdH, and JWJB 
independently extracted data and assessed the quality 
of each included study in duplicate. Any disagreements 
were resolved in consensus meetings.
External validation
External validation of the retrieved models was 
performed in the Hoorn Diabetes Care System cohort, 
a prospective cohort study from the Hoorn region in 
the Netherlands.25 People with type 2 diabetes visit 
the Diabetes Care System in Hoorn once a year to have 
their diabetes monitored and multiple standardised 
measurements taken. Individuals were able to opt-out 
for the anonymous use of their data. We considered 
the year of entry to the study as baseline and used 
data until 31 December 2017 in the current study. 
The data of 12 155 people were included. Age at 
diagnosis was not imputed, and those with missing 
diagnosis dates were excluded (n=705), resulting 
in 11 450 individuals for analysis. Age at diabetes 
diagnosis was based on registry data. All laboratory 
measurements were measured after the participant 
had fasted. Glycated haemoglobin (HbA1c) was 
assessed by turbidimetric inhibition immunoassay of 
haemolysed whole EDTA blood. Blood glucose level 
was assessed in fluorinated plasma with the ultraviolet 
test using hexokinase. Levels of triglycerides, total 
cholesterol, and high density lipoprotein cholesterol 
were determined enzymatically (Cobas c501; Roche 
Diagnostics, Mannheim, Germany). Low density 
lipoprotein cholesterol levels were calculated. Albumin 
was determined by the antigen’s reaction with anti-
albumin antibodies and measured turbidimetrically 
from an overnight first voided urine sample. Creatinine 
concentrations were determined enzymatically in 
heparinised plasma and urine (Cobas c501; Roche 
Diagnostics).
Presence of retinopathy was based on the EURODIAB 
0-5 scale, with grade 0 representing no retinopathy; 
grade 1, minimal non-proliferative retinopathy; 
grade 2, moderate non-proliferative retinopathy; 
grade 3, severe non-proliferative or pre-proliferative 
retinopathy; grade 4, photocoagulated retinopathy; 
and grade 5, proliferative retinopathy.39 Blood pressure 
was measured twice at an interval of three minutes 
using a random zero sphygmomanometer (Hawksley-
Gelmam, Lancing, Sussex, UK). Pulse pressure was 
calculated by subtracting the diastolic blood pressure 
from the systolic blood pressure. Current drug use was 
based on dispensing labels participants took to their 
annual visit. As waist circumference was not available 
in the Hoorn DCS cohort, we estimated this on the 
basis of age, body mass index, and ethnicity using a 
previously published method.40 Cardiovascular events, 
educational level, ethnic background, and smoking 
were self-reported.
Models with the top three highest C statistics 
were validated in GoDARTS, a secondary validation 
cohort (table 1). GoDARTS is a prospective cohort 
comprised of people from the Tayside region, Scotland 
and is described elsewhere.30 Briefly, laboratory 
and prescribing data were obtained from medical 
records and smoking status from a baseline lifestyle 
questionnaire. Weight and height were measured at 
recruitment. Outcomes were defined as described 
in the model development studies (supplementary 
table S10). Given that albumin was relatively sparsely 
available in GoDARTS, models with microalbuminuria 
and macroalbuminuria were not validated, nor were 
models that included albumin as a predictor. A total 
of 8698 people from GoDARTS2 and GoDARTS3 with 
type 2 diabetes were included. The median time to 
chronic kidney disease from recruitment was 4.7 years 
(interquartile range 1.98-6.69) and included follow-up 
data until 2017.
Predicted outcomes
The included outcomes for external validation were 
microalbuminuria, macroalbuminuria, diabetic kidney 
disease, and chronic kidney disease. The outcomes 
defined in our cohort are as described in the individual 
studies. Generally, diabetic kidney disease and 
chronic kidney disease were defined as an estimated 
glomerular filtration rate of <60 mL/min/1.73 m2, 
microalbuminuria as a urinary albumin:creatinine 
ratio ≥30 mg/g, and macroalbuminuria as an 
albumin:creatinine ratio ≥300 mg/g. Supplementary 
table S10 lists the definitions used in each of the 
studies. All models from the original publications were 
considered but were excluded if a missing predictor 
could not be replaced by a proxy or when the frequency 
of events was too low to allow accurate validation. 
The latter was the case for the end stage renal disease 
models, where the incidence was low, with 8, 19, and 
28 cases at the 2, 5, and 10 year horizon, respectively.
Statistical analysis
Missing predictor data were imputed five times using 
the mice function from the R package MICE. Missing 
values ranged from 1.4% for total cholesterol to 6.9% 
for urinary albumin; 2868 individuals had one missing 
variable or more in one of the included predictors. 
Baseline characteristics were given as means with 
standard deviations, and as medians with an 
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interquartile range for not normally distributed data. 
For each validated model, three prediction horizons of 
2, 5, and 10 years were assessed. The performance was 
estimated based on calibration and discrimination. 
Calibration was assessed in three ways: visually by 
plotting the predicted risk against the observed risk in a 
calibration plot, comparing the observed and expected 
outcome, and performing the Hosmer-Lemeshow 
χ2 test. A model is considered well calibrated when 
observed and expected outcome is close to 1 and when 
the observed versus predicted risk fit on the x=y line. 
Given that most retrieved prediction models did not 
report an intercept, we recalibrated all models based 
on the incidence of the Hoorn DCS cohort outcome. 
Two models could not be recalibrated because the base 
risk was small, close to zero (macroalbuminuria in the 
study by Basu et al41 and albuminuria in the study by 
Jardine et al43) and are reported without recalibration. 
Discrimination of the models was evaluated using 
Harrell’s C statistic. All analyses were performed in 
R (version 4.0.2), and figures were produced using 
ggplot2.
Patient and public involvement
Speaking to patient councils inspired this systematic 
review. Study participants and members of the public 




Characteristics of included models
Overall, 10 883 of 11 009 articles screened on title 
and abstract were excluded, leaving 126 for full text 
review. When the full text of papers was screened, a 
total of 87 studies were excluded primarily because the 
studies did not develop a prediction model or because 
the study design was cross sectional (supplementary 
fig S1). Finally, 41 studies were included of which 29 
developed one model or more specifically in people 
with a diagnosis of type 2 diabetes and 12 developed 
one model or more for use in the general population but 
with diabetes as predictor (see supplementary file for 
references of included studies). Overall, these studies 
accounted for 64 prediction models that predicted some 
nephropathy outcome, of which 46 were developed in 
people with diabetes and 18 in the general population 
(supplementary fig S1). The sample size for models 
developed in people with diabetes ranged from 86 to 
660 856 (supplementary table S4). For the general 
population models, the sample size ranged from 
1549 to 799 658 individuals. The models developed 
from data of patients with diabetes mainly predicted 
microalbuminaria, macroalbuminuria, diabetic kidney 
disease, and end stage renal disease as outcomes 
(supplementary table S4). General populations models 
were developed to predict chronic kidney disease 
and end stage renal disease (supplementary table 
S6). Although various prediction horizons were used 
across the models (supplementary table S6), most 
models used a five year prediction horizon. The most 
common predictors for the 42 models developed in 
people with diabetes were age (22 models), estimated 
glomerular filtration rate at baseline (21 models), and 
systolic blood pressure (18 models, supplementary 
table S5). For the 20 general population models, the 
most frequently used predictors in addition to the 
inclusion criterion diabetes were age (14 models) and 
hypertension (eight models, supplementary table S7).
Risk of bias and applicability
Most of the studies scored a high risk of bias in the 
analysis domain (supplementary fig S2a-c), mainly 
as a result of incorrect handling of missing data and 
lack of adjustment for overfitting (supplementary fig 
S2). The participants domain—which covers the data 
source and selection of individuals based on inclusion 
and exclusion criteria—was rated as low risk of bias 
in 68% of the models. The domains predictors and 
outcomes were rated as low risk of bias in 56% and 
51% of the models, respectively. In the remaining 
models these domains were unclearly reported 
(supplementary fig S2a and b). Of the included 
studies, 40% scored high concern for applicability 
to the objectives of the review, as a result of selective 
sampling of the participants or predictors that are not 
typically measured in routine diabetes care, including 
cystatin C and B type natriuretic peptide. Low concern 
for applicability was scored for 44% of the studies for 
all domains (supplementary fig S2a and c).
Apparent performance of the models
The discriminative ability of the prediction models 
was reported through the area under the curve and C 
statistics in 25 development studies in people with type 
2 diabetes. Values ranged from 0.60 (95% confidence 
interval 0.56 to 0.64) to 0.99 (not available) (fig 1). 
Across outcomes, apparent performance varied widely. 
For example, for albuminuria the performance ranged 
from 0.62 (0.61 to 0.64) to 0.84 (0.80 to 0.88) and for 
diabetic kidney disease from 0.61 (0.60 to 0.63) to 
0.81 (0.79 to 0.84) (fig 1). For models developed for 
chronic kidney disease in the general population, the 
performance ranged from 0.70 (not available) to 0.88 
(0.87 to 0.88) (fig 2). For end stage renal disease, the 
performance ranged from 0.60 (0.56 to 0.64) to 0.99 
(not available) in people with type 2 diabetes and 0.85 
(0.83 to 0.86) to 0.96 (0.95 to 0.97) in the general 
population.
In nine studies, calibration was evaluated based 
on the Hosmer-Lemeshow test. One study used the 
Greenwood-D’Agostino-Nam test, and six studies used 
a calibration plot, two merely a description of the 
calibration, and two a calibration table; nine studies 
did not report on calibration (supplementary table 
S4). Almost all studies showed good calibration with 
the Hosmer-Lemeshow test P>0.05. In one study, four 
models did not pass the Greenwood-D’Agostino-Nam 
test for calibration.41
Eleven studies developed in the general population 
reported on discrimination, with C statistics ranging 
from 0.59 (confidence interval not available) to 0.96 
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Fig 1 | Apparent discrimination for models developed in people with type 2 diabetes across studies and outcomes 
(see supplementary file for complete reference list of included studies). Whiskers represent 95% confidence intervals 
or interquartile ranges (Nelson 2019). Two interconnected diamonds represent reported range of C statistics. In 
Basu 2017 composite outcomes were used. Composite 1=doubling of serum creatinine or >20 mL/min/1.73 m2 
decrease in estimated glomerular filtration rate (eGFR); composite 2=macroalbuminuria, renal failure, end stage renal 
disease, doubling of serum creatinine or >20 mL/min/1.73 m2 decrease in eGFR; composite 3=macroalbuminuria, 
microalbuminuria, renal failure, or end stage renal disease. MDRD=Modification of Diet in Renal Disease study; 
eCrCl=estimated creatinine clearance
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(0.95 to 0.97), whereas one study did not report 
discrimination (supplementary table S6). Calibration 
was assessed in eight studies based on the Hosmer-
Lemeshow test and one study based on a calibration 
plot, one study gave a description of the calibration, 
and two studies did not report on the calibration. 
The P values based on the Hosmer-Lemeshow test 
ranged from 0.01 to 0.99, indicating poor to excellent 
calibration, and all models but one passed the test 
(P>0.05).
External validation in Hoorn DCS cohort and 
GoDARTS
Of the 64 identified models, 21 could be externally 
validated; 15 developed in a population with type 2 
diabetes and six in the general population. Studies 
were mainly excluded because they predicted end 
stage renal disease for which the number of events 
was too low in the Hoorn DCS cohort (26 models), with 
fewer than 30 events.42 A second reason for exclusion 
was that the variables in the prediction models were 
not available in the Hoorn DCS cohort, such as serum 
uric acid, cystatin C, and B type natriuretic peptide 
(16 models). Finally, one model was part of a larger 
simulation model (supplementary tables S8 and S9). 
Table 1 shows the baseline characteristics of the the 
Hoorn DCS cohort. The average age was 62.6 years 
(SD 12.1 years), and the median duration of diabetes 
was 0.75 years (intequartile range 0.2-3.8 years). 
Follow-up ranged from one year to 21.7 years. At the 
two year horizon, 1691 people had microalbuminuria, 
263 had macroalbuminuria, and 2159 had an eGFR 
<60 mL/min/1.73 m2 (supplementary table S10). Top 
performing models were validated in the secondary 
cohort, GoDARTS (table 1). The average age in 
GoDARTS was 65.2 (SD 11.1) years, and the median 
duration of diabetes was 7.1 (intequartile range 2.9-
10.4) years.
Discrimination
The discriminatory ability of the models developed 
in people with diabetes varied considerably, with C 
statistics ranging from 0.50 to 0.96 in the Hoorn DCS 
cohort (fig 3). The performance on the two year horizon 
was generally best within a model, followed by the five 
year and 10 year horizons. For most models, however, 
the difference in performance between the horizons 
within a model was smaller than the performance 
between models. In the Hoorn DCS cohort, no apparent 
difference was found in performance between the 
models developed in people with diabetes and the 
general population. In GoDARTS, however, the models 
developed in the general population performed 
generally worse than those developed specifically in 
people with diabetes (fig 3).
The discriminatory ability for albuminuria expressed 
as C statistics ranged from 0.55 (0.54 to 0.56) to 0.96 
(0.95 to 0.97). For macroalbuminuria, two models 
performed well, with C statistics >0.8, whereas the other 
models showed poorer performances, with C statistics 
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Fig 2 | Apparent discrimination for models developed in the general population across studies and outcomes (see 
supplementary file for complete reference list of included studies). Two interconnected diamonds represent reported 
range of C statistics. Whiskers represent 95% confidence intervals
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<0.7. The best performing model was that of Basu et al 
for macroalbuminuria, with a C statistic of 0.96 (0.95 
to 0.97) at the two year horizon (fig 3).41 The model also 
performed well at the five and 10 year horizons, with C 
statistics of 0.91 (0.90 to 0.92) and 0.87 (0.85 to 0.88), 
respectively. The second best performing albuminuria 
model was of Jardine et al, with C statistics of 0.86 
(0.85 to 0.87), 0.84 (0.83 to 0.85), and 0.78 (0.77 to 
0.79) at the 2, 5, and 10 year horizon, respectively (fig 
3).43 Afghahi et al’s model for albuminuria performed 
the worst, with C statistics ranging from 0.55 to 0.59 
for the three horizons (fig 3).44
Four models showed good performance for diabetic 
kidney disease models, with C statistics >0.75, whereas 
the other six models showed poorer performances, 
with C statistics <0.7. Afghahi et al’s model performed 
best, especially when the eGFR was based on the 
Cockcroft-Gault equation, with C statistics of 0.95 
(0.95 to 0.95), 0.93 (0.92 to 0.93), and 0.91 (0.91 to 
0.91) at the 2, 5, and 10 year horizon, respectively (fig 
3).44 The second best model was that of Nelson et al, 
which was based on eGFR from the Modification of Diet 
in Renal Disease study, with C statistics of 0.87 (0.87 
to 0.88), 0.81 (0.81 to 0.82), and 0.76 (0.75 to 0.77) 
at the 2, 5, and 10 year horizon, respectively.28 Dagliati 
et al’s model performed worst, with C statistics of 0.51 
(0.50 to 0.51), 0.52 (0.51 to 0.52), and 0.50 (0.49 to 
0.51) at the 2, 5, and 10 year horizon, respectively.45 
Observed C statistics in the current study’s data were 
similar to the external validation performed in the 
development study, with 0.81 at the five year horizon 
(supplementary table S11). In addition, the C statistic 
of Dunkler et al’s46 model was similar in the current 
study compared with the performance observed by 
Dunkler in their discovery and validation at the five 
year horizon, with C statistics ranging from 0.68 to 
0.70 (supplementary table S11). Good performances 
were observed for Afghahi et al’s model based on eGFR 
from the Modification of Diet in Renal Disease study, 
with C statistics of 0.83 (0.83 to 0.84), 0.80 (0.80 to 
0.81), and 0.78 (0.77 to 0.79) at the 2, 5 and 10 year 
horizon, respectively.44 Of the top three best performing 
models, Afghahi et al’s two models could be validated 
in GoDARTS (fig 3).44 The discrimination in GoDARTS 
outperformed that in the Hoorn DCS cohort, with C 
statistics of 0.99 (0.99 to 0.99) and 0.85 (0.84 to 0.86) 
for the endpoint based on estimated creatine clearance 
and the Modification of Diet in Renal Disease study, 
respectively.
Of the six models for chronic kidney disease 
developed in the general population, a clear distinction 
was apparent between model performance. The C 
statistics for the performance of the top three models 
were >0.8, whereas the remaining models performed 
noticeably worse. Hanratty et al’s model for chronic 
kidney disease performed best, with C statistics of 0.94 
(0.94 to 0.94), 0.90 (0.89 to 0.90), and 0.85 (0.85 to 
0.86) at the 2, 5, and 10 year horizon, respectively.47 
Saranburut et al’s laboratory model also performed 
well, with C statistics at the corresponding three 
horizons of 0.89 (0.89 to 0.90), 0.86 (0.86 to 0.87), 
and 0.84 (0.83 to 0.85).48 The worst performing model 
was that of Wen et al, with C statistics ranging from 
0.57 to 0.59.49 The top three best performing models 
were additionally validated in GoDARTS, where the 
discrimination was considerably lower than in the 
Hoorn DCS cohort (fig 3), with C statistics of 0.74 
(0.73 to 0.75) in Hanratty et al’s model,47 0.75 (0.74 
to 0.76) in Saranburut et al’s model,48 and 0.71 (0.69 
to 0.73) in O’Seaghdha et al’s model.50 The models 
of O’Seaghdha et al50 and Chien et al51 have been 
externally validated in both Nelson et al28 and in 
Fraccaro et al26 (supplementary table S11). In Nelson 
et al’s study,28 the discrimination was similar to the 
C statistics observed in the current study at the five 
year horizon, with a C statistic 0.81. The C statistics 
>0.90 reported in Fraccaro et al26 for both Chien et 
al’s and O’Seaghdha et al’s models were much higher 
than those observed in the Hoorn DCS cohort and 
GoDARTS and in the external validation by Nelson et 
al28 (supplementary table S11).
When the performance of the models was 
investigated between men and women (supplementary 
fig S3), a high correlation was found between the C 
statistics of models in men and women (Pearson’s r 
≥0.96), suggestive of almost identical performance of 
investigated models in both sexes.
Calibration
The calibration of models was generally good after 
recalibration based on the incidence of the specific 
outcome in the Hoorn DCS cohort. Two models 
are reported without recalibration (Basu,41 for 
macroalbuminuria and Jardine,43 for albuminuria). 
Table 1 | Characteristics of external validation cohorts. Values are means (standard 
deviations) unless stated otherwises
Characteristics Hoorn DCS cohort GoDARTS
No 11 450 8698
Age (years) 62.6 (12.1) 65.2 (11.1)
No (%) men 6039 (52.7) 4882 (56)
Median (IQR) diabetes duration (years) 0.75 (0.2-3.8) 7.1 (2.9-10.4)
Body mass index 29.3 (5.4) 31.4 (6.2)
Blood pressure (mm Hg):
 Systolic 141 (20.7) 142 (19)
 Diastolic 80 (10.0) 77 (12)
Cholesterol types (mmol/L):
 Total 5.02 (1.1) 4.4 (0.95)
 Low density lipoprotein 2.97 (1.0) 2.01 (0.77)
 High density lipoprotein 1.22 (0.3) 1.28 (0.39)
 Triglyceride 1.89 (1.2) 1.88 (1.3)
Glucose (mmol/L) 8.37 (2.3)
Median (IQR) HbA1c (mmol/mol) 50.0 (44.3-60.7) 54.1 (46.4-65.03)
HbA1c (%) 6.7 (6.2 to 7.7) 7.1 (6.4-8.1)
No (%) current smoker 2438 (21) 1427 (16.4)
No (%) of European descent 10 372 (90.6) 8698 (100)
No (%) using antihypertensives 6592 (57.6) 7075 (82)
No (%) using lipid lowering drugs 4697 (41) 7781 (90)
No (%) using glucose lowering drugs:
 None 3349 (29.2) 2671 (30.7)
 Oral 6893 (60.2) 4515 (52.0)
 Oral+insulin 574 (5.0) 377 (4.3)
 Insulin 634 (5.5) 1135 (13.0)
DCS=Diabetes Care System; GoDARTS=Genetics of Diabetes Audit and Research in Tayside Scotland; 
IQR=interquartile range.
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Two of the five models developed for albuminuria 
(Basu,41 Jardine,43 supplementary fig S4) showed an 
overestimation of the risk, whereas the other three 
models showed good calibration. No differences were 
observed between horizons. All albuminuria models 
were significant in the Hosmer-Lemeshow χ2 test, 
except for Basu et al’s microalbuminuria model.41 
The models developed for diabetic kidney disease 
developed well in terms of observed to expected ratios, 
with ratios ≥0.99 in nine models. The three models 
of Basu et al41 and two models of Dunkler et al46 
showed the best calibration (supplementary fig S5h). 
The poorest calibration was observed for the models 
of Low et al52 and Dagliati et al45 (supplementary fig 
S5). Again, the model of Basu et al showed the best 
calibration (supplementary fig S5h). The observed to 
expected ratios were generally close to 1, with Nelson 
et al’s model having the highest deviation.28
Five of the six general population models showed 
good calibration based on observed to expected ratios. 
Calibration was best for Saranburut et al’s clinical 
model.48 Chien et al’s model showed an overestimation 
of risk51 (supplementary fig S6).
Discussion
We conducted a systematic review and quality 
assessment of prediction models for nephropathy in 
people with type 2 diabetes. Overall, 46 models were 
developed in a type 2 diabetes population and 18 
in the general population. These studies accounted 
for a total of 64 prediction models for albuminuria, 
renal impairment, diabetic kidney disease, chronic 
kidney disease, and end stage renal disease. Of the 
64 prediction models, 21 were externally validated in 
the Hoorn Diabetes Care System cohort. The reported 
discrimination of the models varied considerably 
across outcomes and models and, to some extent, 
prediction horizon. Multiple models performed well, 
with C statistics >0.80 for the three investigated 
outcomes of albuminuria, chronic kidney disease, 
and diabetic kidney disease. The calibration showed 
the same variation between outcomes and studies 
compared with the discrimination, but to a lesser 
extent between horizons. The models performed better 
in terms of discrimination at the two year horizon 
compared with the 5 and 10 year horizons. For most 
models, however, the difference in performance 
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Fig 3 | Discriminatory ability of models included in external validation by outcome and prediction horizons. Whiskers represent 95% confidence 
intervals. See supplementary file for complete reference list of included studies. In Basu 2017 three composite outcomes were defined: composite 
1=doubling of serum creatinine or >20 mL/min/1.73m2 decrease in estimated glomerular filtration rate (eGFR); composite 2=macroalbuminuria, 
renal failure, end stage renal disease, and doubling of serum creatinine or >20 mL/min/1.73m2 decrease in eGFR; composite 3=macroalbuminuria, 
microalbuminuria, renal failure, or end stage renal disease. DCS=Diabetes Care System; MDRD=Modification of Diet in Renal Disease study; 
eCrCl=estimated creatinine clearance
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between the horizons within a model was smaller than 
the performance between models. Models developed 
in people with diabetes did, in general, perform similar 
to models developed in the general population.
Principal findings
Of the five validated models for albuminuria, those 
by Basu et al41 and Jardine et al43 performed best in 
terms of discrimination. Basu et al’s models showed 
better calibration than Jardine et al’s models. Jardine 
et al’s model has eight predictors compared with 14 
in Basu et al’s model. In terms of clinical practicality, 
both models are equal and contain routinely available 
predictors. Basu et al’s model, however, has the 
highest number of predictors, including less common 
accessible predictors, such as cardiovascular disease 
and the use of anticoagulants.
Ten models for diabetic kidney disease were 
validated. In terms of discrimination, the two models 
of Afghahi et al44 and the model of Nelson et al28 
performed best. The estimated creatinine clearance of 
the model of Afghahi et al44 uses six and the model of 
Nelson et al28 uses 12 routinely available predictors. 
In terms of calibration, the model of Afghahi et al 
outperformed that of Nelson et al.28 Models with fewer 
variables, such as the those of Afghahi et al44 and 
Saranburut et al,48 especially in resource poor settings, 
might be more useful than models with many variables, 
such as Nelson et al’s model28 (supplementary table 
S12). Furthermore, both models of Afghahi et al44 also 
showed excellent discrimination in GoDARTS.
For the models developed for chronic kidney 
disease in the general population, Hanratty et al’s 
model47 and Saranburut et al’s laboratory model48 
performed well in a population with type 2 diabetes. 
Saranburut et al’s model, however, showed a better 
calibration than Hanratty et al’s model. Both models 
contain routinely available predictors, with five (age, 
diabetes, peripheral vascular disease, eGFR, period 
of observation) predictors in Hanratty et al’s model 
and six predictors (age, sex, systolic blood pressure, 
waist circumference, diabetes, eGFR) in Saranburut et 
al’s model, and could therefore be applied in clinical 
practice (supplementary table S12). The discrimination 
of Hanratty et al’s and Saranburut et al’s models was 
lower in GoDARTS.
Implications
As the number of people with type 2 diabetes increases 
worldwide, the incidence of diabetic kidney disease 
will also increase. It is therefore vital to identify those 
at higher risk of nephropathy to be able to enhance 
monitoring and possibly to intervene at an early stage 
to slow down renal decline. Interventions include 
intensified glycaemic control; nephroprotective 
glucose lowering drugs, including glucagon-like 
peptide 1 receptor antagonists and sodium-glucose 
cotransporter 2 inhibitors; blood pressure control; 
and renin-angiotensin system inhibition.14-17 More 
stringent glycaemic control has been suggested 
to reduce the development and worsening of 
nephropathy.13 Prediction models will help to estimate 
the risk of diabetic kidney disease, especially when 
the models are based on routine clinical markers. 
Our results show that for the endpoints albuminuria, 
diabetic kidney disease, and chronic kidney disease, 
prediction models are available with the capability 
of reliably discriminating between people with a low 
and a high risk. In the validation study, models that 
predict chronic kidney disease and diabetic kidney 
disease (eGFR <60 mL/min/1.73m2) performed well 
across all three prediction horizons, which could give 
people with diabetes an estimation of risk for the near 
future (two year risk) and in the long term (10 year). 
For example, Saranburut et al’s model48 and Afghahi 
et al’s model44 both showed good discrimination and 
validation. However, we observed that the two year 
horizon outperformed the 5 and 10 year horizons, 
which is not unexpected given that baseline measures 
are more likely to predict the near future accurately. 
In contrast, in the long term, much can change in 
terms of, for example, changes in lifestyle or treatment 
regimens and thus outcome events.
Strengths and limitations of this study
This systemic review has some limitations and 
strengths. One limitation is that we excluded 
articles that were not in English or Dutch. During 
full text screening, although we excluded three 
studies based on language,44-46 we were still able 
to review the reference lists for additional eligible 
studies. Other partially comparable systematic 
reviews did not include any of these three studies as 
relevant prediction models.23 25 53 Therefore, it can 
be questioned whether the excluded studies were 
relevant to this systematic review. A second limitation 
is that we could not validate models that predicted 
end stage renal disease because of too limited events 
in our study population; more investigation is needed. 
The options to intervene in end stage renal disease are 
limited, and as such interventions ideally should occur 
earlier. A third limitation is that the Hoorn DCS cohort 
comprised people with generally well controlled 
diabetes. As such, models developed on high risk 
populations performed less well in the external 
validation in contrast with models developed on lower 
risk populations. Finally, we were unable to use several 
models because comparable measurements were not 
available in the Hoorn DCS cohort. However, given that 
these variables were not measured as part of routine 
care is an indication of their limited applicability.
The study’s strengths include the systematic review 
to identify relevant prognostic models and quality 
assessment of the included studies. Secondly, we 
externally validated the models in a large prospective 
cohort study with long term follow-up and detailed 
phenotyping based on routine care data thus enabling 
a head-to-head comparison of the models. Thirdly, 
we validated models with the best discrimination in 
a secondary cohort from a different country. Future 
studies should evaluate the generalisability of the 
models in people with other forms of diabetes and to 
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what extent these models have been implemented in 
day to day clinical practice.
Conclusion
Many prognostic models are available to predict 
nephropathy in people with type 2 diabetes. We 
identified 64 prediction models, 21 of which could 
be validated and directly compared in the Hoorn DCS 
cohort. For each of the three included outcomes of 
albuminuria, diabetic kidney disease, and chronic 
kidney disease, discrimination and calibration varied 
considerably across horizons and models. Several 
models showed good discrimination and calibration 
across various prediction horizons for each outcome, 
although models performed best at the 2 year horizon. 
In a secondary validation cohort, models developed 
for diabetic kidney disease especially showed good 
discrimination compared with those developed for 
chronic kidney disease. This study identified several 
suitable models that will contribute to preventing or 
postponing renal decline and ultimately end stage 
renal disease in people with diabetes.
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